Two of Thailand's leading hospital groups have teamed up to bring one of the most advanced cancer treatments in the world to Southeast Asian patients. The catch? China has been doing this for years, and at real scale.
Thailand's medical tourism reputation has long rested on cosmetic surgery and elective procedures. That image is starting to shift. The Faculty of Medicine Ramathibodi Hospital, part of Mahidol University, and the Samitivej Hospital Group announced a joint initiative to research and deliver CAR-T cell therapy — a highly personalized form of immunotherapy that reprograms a patient's own immune cells to hunt and destroy cancer. The announcement was a milestone at the Cell Therapy & Gene Therapy Symposium 2025 held last September in Bangkok, but it has drawn fresh attention as the program moves toward wider clinical deployment in 2026.
The numbers are striking. According to Ramathibodi and Samitivej, CAR-T therapy can potentially cure up to 70% of patients with certain types of leukemia and lymphoma who have not responded to conventional treatments. That is a significant claim — and one that comes with a equally significant price tag attached to Western versions of the therapy, which can exceed USD $500,000 per treatment course. The Thai hospitals say their program aims to bring the cost down by more than five times compared to current US and European pricing.
The public-to-private structure here is unusual. Ramathibodi, a major public academic medical center, is partnering with Samitivej, a private hospital group that already draws significant international patient volume. Moving cutting-edge cell therapy from a research hospital into a commercial medical tourism setting is a first for Thailand — and signals a deliberate attempt to position the country as a serious contender in advanced oncology.
Thailand's announcement will likely draw comparisons to China's CAR-T sector, and for good reason. China has approved multiple CAR-T therapies through the National Medical Products Administration (NMPA), building one of the world's largest pipelines of domestically developed cell therapies. The most recent milestone came in late 2025 when Juventus Cell Therapy's Inaticabtagene Autoleucel (YORWIDA) became China's first domestically developed CAR-T product with dual indications covering both leukemia and lymphoma — two major hematologic cancers — in a single therapy.
China has also approved CAR-T products specifically for pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), a condition that disproportionately affects children and young adults. Clinical data from Chinese trials has shown overall response rates of 79–89% in B-cell malignancies and a 64% 12-month progression-free survival rate — figures that rival the outcomes reported at leading Western cancer centers.
Major cancer hospitals involved in CAR-T delivery in China include Peking University Cancer Hospital, Shanghai Ruijin Hospital, and multiple centers affiliated with the Chinese Academy of Medical Sciences. The infrastructure is well established, with dedicated cell therapy wards, established logistics for apheresis and reinfusion, and a growing number of treating physicians with hands-on experience.
| Factor | Thailand | China |
|---|---|---|
| CAR-T Development Stage | Early clinical deployment; public-private partnership launching | Mature; multiple NMPA-approved products in clinical use since 2021 |
| Approved Indications | Leukemia and lymphoma (B-cell); expanding to myeloma, brain cancer in future | Leukemia, lymphoma (adult and pediatric); large B-cell lymphoma, r/r B-ALL |
| Clinical Response Rate | Up to 70% potential cure rate (based on international benchmarks) | 79–89% overall response rate in B-cell malignancies |
| Estimated Treatment Cost | Target: 5x cheaper than Western pricing (est. $80,000–$100,000) | Approximately $50,000–$120,000 per treatment course (domestic products) |
| Experience & Volume | Limited; program in early rollout phase | High patient volumes; established treatment protocols at major cancer centers |
| Medical Tourism Infrastructure | Strong; internationally accredited hospitals, established patient pathways | Growing rapidly; JCI-accredited cancer centers, language support improving |
| Waiting Time | Short initial intake; program scaling up | Variable; major centers may have 2–6 week wait for treatment slots |
Our coordination team can help you understand which hospitals offer CAR-T treatment, what the approval process involves for international patients, and provide cost estimates tailored to your diagnosis.
Get a Free Consultation